Boston, MA 10/01/2013 (wallstreetpr) – Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) is a very promising biotechnology company. It has a newly-approved product line that is called Lymphoseek. Very recently the company completed an offering worth $30M in registered common-stock. It definitely looks like a good time to consider this stock.
Recently, Navidea announced a registered PO of 10,563,381 common stock shares as well as warrants to buy up to 3,169,015 common stock shares at $2.84/ unit. This results in a net of approximately $28.8 million. A quick peek at the $2.84 purchase price makes the stock desirable. Another reason to consider this stock is that the accredited institutional investor, Crede Capital Group owns a large percentage of the stock.
Another noteworthy point is that the warrant-exercise is $3.83. This amounts to a premium of around 35%. From an investor’s perspective, it shows a lot of muscle and adds to Navidea’s value.
For the quarter that ended 30 June 2013, Navidea pulled in revenue of $195,000. Since the company is an infancy-stage it would not be appropriate to weigh too-heavily on the $195,000 revenue that it had in the last quarter. The company had cash and cash-equivalents of $25.6 million prior to its Crede deal.
In Monday’s trading session, Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) dropped by 1.49%. The company’s shares opened at a price of $2.66, climbed to an intraday high of $2.71 and dropped to a close of $2.65. Approximately 0.674 million shares were traded on Monday while an average volume of 0.535 million shares were traded over 30 days. The 52-week low of the shares is $2.14 while the 52-week high is $3.59. Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) has a market capitalization of $352.11.
About the company
Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) was previously Neoprobe Corporation. It is a bio-pharmaceutical company that focuses on developing and commercializing precision diagnostic-agents.